
Laurent Savale

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5680192/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. Circulation, 2012, 125, 2128-2137.	1.6	548
2	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. European Respiratory Journal, 2017, 50, 1700889.	3.1	527
3	Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. JAMA - Journal of the American Medical Association, 2021, 325, 1525.	3.8	434
4	A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. New England Journal of Medicine, 2011, 365, 44-53.	13.9	432
5	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. European Respiratory Journal, 2014, 43, 1691-1697.	3.1	319
6	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. European Respiratory Journal, 2020, 56, 2001634.	3.1	284
7	Portopulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 637-643.	2.5	220
8	Criteria for diagnosis of exercise pulmonary hypertension. European Respiratory Journal, 2015, 46, 728-737.	3.1	213
9	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 2019, 53, 1802095.	3.1	173
10	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 2018, 137, 693-704.	1.6	155
11	Chemotherapy-Induced Pulmonary Hypertension. American Journal of Pathology, 2015, 185, 356-371.	1.9	149
12	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. European Respiratory Journal, 2019, 53, 1801906.	3.1	144
13	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. European Respiratory Journal, 2018, 51, 1700745.	3.1	136
14	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. Journal of Clinical Investigation, 2018, 128, 1956-1970.	3.9	125
15	Initial dual oral combination therapy in pulmonary arterial hypertension. European Respiratory Journal, 2016, 47, 1727-1736.	3.1	124
16	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respiratory Medicine,the, 2019, 7, 594-604.	5.2	119
17	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. European Respiratory Journal, 2017, 50, 1700465.	3.1	111
18	Post-acute COVID-19 syndrome. European Respiratory Review, 2022, 31, 210185.	3.0	105

#	Article	IF	CITATIONS
19	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 842-854.	2.5	94
20	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. European Respiratory Journal, 2013, 41, 96-103.	3.1	92
21	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. Journal of Heart and Lung Transplantation, 2012, 31, 150-158.	0.3	91
22	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. European Respiratory Journal, 2020, 56, 2001875.	3.1	90
23	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal, 2017, 50, 1700217.	3.1	89
24	Genetic counselling in a national referral centre for pulmonary hypertension. European Respiratory Journal, 2016, 47, 541-552.	3.1	87
25	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. European Respiratory Journal, 2022, 59, 2102419.	3.1	83
26	De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome. Journal of Heart and Lung Transplantation, 2016, 35, 1067-1077.	0.3	81
27	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. Circulation Research, 2019, 124, 846-855.	2.0	81
28	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2014, 44, 1627-1634.	3.1	80
29	Portopulmonary hypertension in the current era of pulmonary hypertension management. Journal of Hepatology, 2020, 73, 130-139.	1.8	78
30	Longâ€ŧerm outcome in liver transplantation candidates with portopulmonary hypertension. Hepatology, 2017, 65, 1683-1692.	3.6	68
31	Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. Journal of Heart and Lung Transplantation, 2018, 37, 903-911.	0.3	64
32	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. European Respiratory Journal, 2018, 52, 1800678.	3.1	60
33	Screening for pulmonary arterial hypertension in systemic sclerosis. European Respiratory Review, 2019, 28, 190023.	3.0	59
34	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. Chest, 2016, 149, 353-361.	0.4	55
35	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. Cardiovascular Research, 2020, 116, 686-697.	1.8	54
36	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. Journal of Heart and Lung Transplantation, 2018, 37, 647-655.	0.3	50

#	Article	IF	CITATIONS
37	Screening for pulmonary arterial hypertension in adults carrying a <i>BMPR2</i> mutation. European Respiratory Journal, 2021, 58, 2004229.	3.1	50
38	Acute decompensated pulmonary hypertension. European Respiratory Review, 2017, 26, 170092.	3.0	48
39	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. Medicine (United States), 2015, 94, e1800.	0.4	46
40	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. European Respiratory Journal, 2016, 48, 1517-1519.	3.1	44
41	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. European Respiratory Journal, 2021, 58, 2100116.	3.1	41
42	Phenotype and outcome of pulmonary arterial hypertension patients carrying a <i>TBX4</i> mutation. European Respiratory Journal, 2020, 55, 1902340.	3.1	40
43	Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. European Respiratory Journal, 2020, 56, 2001808.	3.1	38
44	Pulmonary arterial hypertension in patients treated with interferon. European Respiratory Journal, 2015, 46, 1851-1853.	3.1	35
45	Lung transplantation for sarcoidosis: outcome and prognostic factors. European Respiratory Journal, 2021, 58, 2003358.	3.1	32
46	Portopulmonary Hypertension. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 651-661.	0.8	30
47	Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. European Journal of Cardio-thoracic Surgery, 2018, 54, 341-347.	0.6	30
48	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. Annals of Thoracic Surgery, 2017, 104, 404-411.	0.7	29
49	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. European Respiratory Journal, 2020, 56, 2000279.	3.1	28
50	Serum and pulmonary uric acid in pulmonary arterial hypertension. European Respiratory Journal, 2021, 58, 2000332.	3.1	28
51	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. European Respiratory Review, 2022, 31, 210165.	3.0	28
52	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. American Journal of Cardiovascular Drugs, 2015, 15, 13-26.	1.0	27
53	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. Cardiovascular Research, 2022, 118, 1805-1820.	1.8	26
54	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. European Respiratory Journal, 2020, 55, 1802108.	3.1	24

#	Article	IF	CITATIONS
55	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. Cardiovascular Research, 2021, 117, 1391-1401.	1.8	23
56	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. FASEB Journal, 2019, 33, 3670-3679.	0.2	22
57	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. European Respiratory Review, 2018, 27, 180004.	3.0	21
58	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 4105.	1.8	21
59	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. European Respiratory Journal, 2018, 52, 1800272.	3.1	21
60	Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. European Respiratory Journal, 2021, 58, 2101090.	3.1	18
61	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. Journal of Heart and Lung Transplantation, 2022, 41, 1135-1194.	0.3	17
62	Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. European Heart Journal Supplements, 2019, 21, K37-K45.	0.0	16
63	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. ERJ Open Research, 2022, 8, 00479-2021.	1.1	16
64	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. European Respiratory Journal, 2019, 54, 1900585.	3.1	15
65	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. PLoS ONE, 2020, 15, e0243961.	1.1	15
66	An emerging phenotype of pulmonary arterial hypertension patients carrying <i>SOX17</i> variants. European Respiratory Journal, 2022, 60, 2200656.	3.1	15
67	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. Chest, 2021, 159, 1197-1207.	0.4	14
68	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. European Respiratory Journal, 2021, 58, 2004066.	3.1	14
69	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 843-852.	2.5	12
70	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. European Respiratory Journal, 2021, 57, 2002208.	3.1	12
71	Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre. Archives of Cardiovascular Diseases, 2021, 114, 221-231.	0.7	11
72	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. Chest, 2018, 154, 882-892.	0.4	10

#	Article	IF	CITATIONS
73	Congenital portosystemic shunts. Clinics and Research in Hepatology and Gastroenterology, 2020, 44, 452-459.	0.7	10
74	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. European Respiratory Journal, 2021, 58, 2100466.	3.1	7
75	Lung transplantation in HIV-positive patients: a European retrospective cohort study. European Respiratory Journal, 2022, 60, 2200189.	3.1	7
76	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. Journal of Heart and Lung Transplantation, 2022, 41, 1285-1293.	0.3	6
77	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. British Journal of Anaesthesia, 2020, 125, e466-e468.	1.5	5
78	The isobaric pulmonary arterial compliance in pulmonary hypertension. ERJ Open Research, 2021, 7, 00941-2020.	1.1	5
79	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiographyâ€based cluster analysis. American Journal of Hematology, 2021, 96, 1166-1175.	2.0	5
80	Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. European Respiratory Journal, 2022, 60, 2200107.	3.1	5
81	Pumpless Lung Assist as a Bridge to Medical Therapy in a Teenager With Pulmonary Arterial Hypertension and Partial Anomalous Pulmonary Venous Return. Canadian Journal of Cardiology, 2020, 36, 1831.e7-1831.e9.	0.8	4
82	Portopulmonary Hypertension. Chest, 2012, 141, 840-842.	0.4	3
83	Our current understanding of and approach to the management of lung cancer with pulmonary hypertension. Expert Review of Respiratory Medicine, 2021, 15, 373-384.	1.0	3
84	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. European Respiratory Journal, 2021, 57, 2003132.	3.1	3
85	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. Journal of Clinical Immunology, 2021, 41, 1549-1562.	2.0	3
86	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. American Journal of Transplantation, 2021, 21, 3388-3400.	2.6	3
87	Pulmonary hypertension associated with busulfan. Pulmonary Circulation, 2021, 11, 1-12.	0.8	3
88	Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. European Respiratory Journal, 2022, 59, 2102388.	3.1	3
89	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. Pulmonary Circulation, 2022, 12, e12023.	0.8	2
90	A <scp>CELSR1</scp> variant in a patient with pulmonary arterial hypertension. Clinical Genetics, 2021, 100, 771-772.	1.0	1

#	Article	IF	CITATIONS
91	Endothelial dysfunction and hypercoagulability in severe sickle-cell acute chest syndrome. ERJ Open Research, 2021, 7, 00496-2021.	1.1	1
92	Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading. , 2018, , .		1
93	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. Respiratory Medicine, 2020, , 123-134.	0.1	1
94	Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension. , 2021, , 301-316.		0
95	Reply to: Jin et al. and Sun et al American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
96	Right heart failure. , 0, , 32-47.		0
97	Title is missing!. , 2020, 15, e0243961.		0
98	Title is missing!. , 2020, 15, e0243961.		0
99	Title is missing!. , 2020, 15, e0243961.		0
100	Title is missing!. , 2020, 15, e0243961.		0